Format

Send to

Choose Destination
Glob Adv Health Med. 2012 Mar;1(1):18-25. doi: 10.7453/gahmj.2012.1.1.006.

Durable Regression of Primary Cutaneous B-Cell Lymphoma Following Fever-inducing Mistletoe Treatment: Two Case Reports.

Author information

1
Maurice Orange, MSc, is a general practitioner, formerly medical director at Park Attwood Clinic, United Kingdom, and currently senior hospital doctor integrative oncology at the Ita Wegman Klinik, Arlesheim.

Abstract

in English, Chinese, Spanish

BACKGROUND:

Mistletoe is a complementary cancer treatment that is widely used, usually in addition to and alongside recommended conventional cancer therapy. However, little is known about its use, effectiveness, and safety in the treatment of cutaneous lymphoma.

CASE REPORT:

Two patients with primary cutaneous B-cell lymphoma (pT2bcNxM0 follicle center and pT2ac-NxM0 marginal zone) either declined or postponed recommended conventional treatment and received high-dose, fever-inducing mistletoe treatment; a combination of intratumoral, subcutaneous, and intravenous application was given; and one patient also underwent whole-body hyperthermia. The lymphoma regressed over a period of 12 and 8 months, respectively, and after administration of a cumulative dose of 12.98 g and 4.63 g mistletoe extract, respectively. The patients are in remission to date, 3.5 years after commencement of treatment. Neither patient received conventional cancer treatment during the entire observation period.

KEYWORDS:

Lymphoma; Mistletoe treatment; PCBCL; PCFCL; PCMZL; cancer; fever; primary cutaneous B-cell lymphoma; tumor

Supplemental Content

Full text links

Icon for Atypon Icon for PubMed Central
Loading ...
Support Center